Tags

Type your tag names separated by a space and hit enter

Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths.
J Infect Dis. 1999 Apr; 179(4):996-1003.JI

Abstract

A double-blind placebo-controlled study of the concurrent administration of albendazole and praziquantel was conducted in>1500 children with high prevalences of geohelminths and schistosomiasis. The study sites were in China and the Philippines, including 2 strains of Schistosoma japonicum, and 2 different regions of Kenya, 1 each with endemic Schistosoma mansoni or Schistosoma haematobium. Neither medication affected the cure rate of the other. There was no difference between the side effect rate from albendazole or the double placebo. Praziquantel-treated children had more nausea, abdominal pain, and headache but these side effects were statistically more common in children with schistosomiasis, suggesting a strong influence of dying parasites. The subjects were followed for 6 months for changes in infection status, growth parameters, hemoglobin, and schistosomiasis morbidity. In all 4 sites, a significant 6-month increase in serum hemoglobin was observed in children who received praziquantel, strongly supporting population-based mass treatment.

Authors+Show Affiliations

Case Western Reserve University, Cleveland, Ohio, USA. golds@metrohealth.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10068597

Citation

Olds, G R., et al. "Double-blind Placebo-controlled Study of Concurrent Administration of Albendazole and Praziquantel in Schoolchildren With Schistosomiasis and Geohelminths." The Journal of Infectious Diseases, vol. 179, no. 4, 1999, pp. 996-1003.
Olds GR, King C, Hewlett J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179(4):996-1003.
Olds, G. R., King, C., Hewlett, J., Olveda, R., Wu, G., Ouma, J., Peters, P., McGarvey, S., Odhiambo, O., Koech, D., Liu, C. Y., Aligui, G., Gachihi, G., Kombe, Y., Parraga, I., Ramirez, B., Whalen, C., Horton, R. J., & Reeve, P. (1999). Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. The Journal of Infectious Diseases, 179(4), 996-1003.
Olds GR, et al. Double-blind Placebo-controlled Study of Concurrent Administration of Albendazole and Praziquantel in Schoolchildren With Schistosomiasis and Geohelminths. J Infect Dis. 1999;179(4):996-1003. PubMed PMID: 10068597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. AU - Olds,G R, AU - King,C, AU - Hewlett,J, AU - Olveda,R, AU - Wu,G, AU - Ouma,J, AU - Peters,P, AU - McGarvey,S, AU - Odhiambo,O, AU - Koech,D, AU - Liu,C Y, AU - Aligui,G, AU - Gachihi,G, AU - Kombe,Y, AU - Parraga,I, AU - Ramirez,B, AU - Whalen,C, AU - Horton,R J, AU - Reeve,P, PY - 1999/3/9/pubmed PY - 2000/3/21/medline PY - 1999/3/9/entrez SP - 996 EP - 1003 JF - The Journal of infectious diseases JO - J Infect Dis VL - 179 IS - 4 N2 - A double-blind placebo-controlled study of the concurrent administration of albendazole and praziquantel was conducted in>1500 children with high prevalences of geohelminths and schistosomiasis. The study sites were in China and the Philippines, including 2 strains of Schistosoma japonicum, and 2 different regions of Kenya, 1 each with endemic Schistosoma mansoni or Schistosoma haematobium. Neither medication affected the cure rate of the other. There was no difference between the side effect rate from albendazole or the double placebo. Praziquantel-treated children had more nausea, abdominal pain, and headache but these side effects were statistically more common in children with schistosomiasis, suggesting a strong influence of dying parasites. The subjects were followed for 6 months for changes in infection status, growth parameters, hemoglobin, and schistosomiasis morbidity. In all 4 sites, a significant 6-month increase in serum hemoglobin was observed in children who received praziquantel, strongly supporting population-based mass treatment. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/10068597/Double_blind_placebo_controlled_study_of_concurrent_administration_of_albendazole_and_praziquantel_in_schoolchildren_with_schistosomiasis_and_geohelminths_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/314686 DB - PRIME DP - Unbound Medicine ER -